ClinicalTrials.gg
CompletedNCT02891837Updated Feb 23, 2023Results posted

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

A Phase 3 interventional study of L-citrulline and Placebo in Acute Lung Injury, sponsored by Asklepion Pharmaceuticals, LLC. Completed at 29 sites in 4 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2023-02-23.

Sponsored by Asklepion Pharmaceuticals, LLC · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.

Enrollment
23rd of 88
189 · median 68
Started
2016
with 1 other
Phase 3
11 of 112
1 open now
Registered
64th of 112
by date

Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 23rd largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 64th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Acute Lung Injury with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether L-citrulline is effective and safe in the prevention of clinical sequelae of Acute Lung Injury in pediatric subjects undergoing surgery for congenital heart defects.

Read the detailed description

This is a randomized, double-blind, placebo controlled, multicenter study that will compare the efficacy and safety of L-citrulline versus placebo in subjects undergoing surgery for congenital heart defects.

Eligible subjects undergoing repair of a large unrestrictive ventricular septal defect (VSD), a partial or complete atrioventricular septal defect (AVSD), or an ostium primum atrial septal defect (primum ASD) will be eligible for enrollment in this study.

Each enrolled subject will be randomized to receive either L-citrulline or placebo throughout all administrations in the study. Subjects will receive an L-citrulline bolus of 150 mg/kg or placebo at the initiation of cardiopulmonary bypass, the addition of L-citrulline at a concentration of 200 μmol/L or placebo given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L. L-citrulline bolus of 20 mg/kg or placebo 30 minutes after decannulation from cardiopulmonary bypass, followed immediately by a 9 mg/kg/hr continuous L-citrulline infusion or placebo for up to 48 hours.

The study drug or placebo infusion will be discontinued once invasive arterial blood pressure monitoring is discontinued or at 48 hours, whichever comes first. Subjects will be followed until Day 28 or discharge from the hospital, whichever comes first. For subjects discharged prior to Day 28, a final assessment via telephone will be conducted at Day 28.

03

Conditions studied

  • Acute Lung Injury

Keywords

  • L-citrulline
  • pediatric
  • Lung Injury
  • Bypass
  • Heart Defects
  • Clinical Sequelae
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects, parents, or legal guardian of the subject who are willing and able to sign
  • Male and female subjects aged ≤18 years of age
  • Infants, children and adolescents undergoing cardiopulmonary bypass (CPB) for repair of a large unrestrictive VSD, an ostium primum ASD, or a partial or complete AVSD
  • Pre-operative echocardiogram which confirms the cardiovascular anatomy and defect to be surgically repaired

Exclusion criteria

Exclusion Criteria:

  • Evidence of pulmonary artery or vein abnormalities on the pre-operative echocardiogram that will not be addressed surgically. Specific abnormalities excluded include the following:

    • Significant pulmonary artery narrowing not amenable to surgical correction
    • Previous pulmonary artery stent placement
    • Significant left sided AV valve regurgitation not amenable to surgical correction
    • Pulmonary venous return abnormalities not amenable to surgical correction
    • Pulmonary vein stenosis not amenable to surgical correction
  • Preoperative requirement for mechanical ventilation or intravenous inotrope support
  • Presence of fixed or idiopathic pulmonary hypertension (i.e. Eisenmenger's Syndrome) prior to surgical repair
  • Pre-operative use of medications to treat pulmonary hypertension
  • Pregnancy; Females of must be willing to participate an acceptable method of for the duration of study participation (e.g. oral contraceptive, hormonal implant, intra-uterine device)
  • Any condition which, in the opinion of the investigator, might interfere with the study objectives
  • Participation in another clinical trial within 30 days of Screening or while participating in the current study, including the 28 days of follow-up post study drug administration
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    L-citrulline

    * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base; * Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.

    Drug: L-citrulline

  • Placebo comparator
    Placebo

    * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass; * Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.

    Other: Placebo

Interventions

  • * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base; * Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.

  • OtherPlacebo

    * Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass; * Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass; * Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass; * 9 mg/kg/hr continuous infusion for up to 48 hours.

06

What researchers measure

Primary outcomes

  1. A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.

    Mechanical ventilation (MV) = invasive or noninvasive MV incl. bilevel (biphasic) positive airway pressure or continuous positive airway pressure. Inotrope use = medications considered within the derivation of total inotrope score (dopamine, dobutamine, milrinone, epinephrine, phenylephrine, norepinephrine). Both measures recorded until earliest of subject hospital discharge or Day 28.

    Time frame: 28 Days

Secondary outcomes

  1. Length of Time on Mechanical Ventilation

    The same definitions and analyses as described for the primary endpoint will be applied.

    Time frame: 28 Days

  2. Length of Time on Positive Pressure Ventilation

    The same definitions and analyses as described for the primary endpoint will be applied.

    Time frame: 28 Days

  3. Length of Time of Inotrope Use

    The same definitions and analyses as described for the primary endpoint will be applied.

    Time frame: 28 days

  4. Inotrope Score

    Inotrope score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower inotrope score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower inotrope score in the citrulline group when compared to the placebo group. In this study, the score was calculated each hour post-operatively from the time of separation from bypass until the completion of study drug. Additionally, the total inotrope score over time until Day 28 or hospital discharge was derived. Inotrope score was calculated using the following formula: Total inotrope score = Dopamine dose (µg/kg/min) + Dobutamine dose (µg/kg/min) + 10 \* Milrinone dose (µg/kg/min) + 100 \* Epinephrine dose (µg/kg/min) + 100 \* Phenylephrine dose (µg/kg/min) + 100 \* Norepinephrine dose (µg/kg/min).

    Time frame: Up to 48 hours after separation from CBP

  5. Hemodynamic Improvement: Heart Rate

    Heart rate at hours 1, 2, 4, 12, 24 and 48.

    Time frame: 2 Days

  6. Hemodynamic Improvement: Systemic Arterial Blood Pressure

    Systemic arterial blood pressure at hours 1, 2, 4, 12, 24 and 48.

    Time frame: 2 Days

  7. Hemodynamic Improvement: Oxygen Saturation

    Oxygen saturation at hours 1, 2, 4, 12, 24 and 48.

    Time frame: 2 Days

  8. Hemodynamic Improvement: Central Venous Pressure

    Central venous pressure at hours 1, 2, 4, 12, 24 and 48.

    Time frame: 2 Days

  9. Thoracotomy Output

    The thoracotomy output is defined as the total volume of chest tube drainage recorded in cc prior to discontinuation of chest intubation. The total postoperative duration (in hours) that the chest tube is used will be calculated as the time from the end of the surgery to the time the chest tube is removed. If an additional chest tube is required or reinserted (until discharge from the hospital or at Day 28) the duration that the additional chest tube was used (from time of insertion to time of removal) will be added to the time the original chest tube was used for the total postoperative duration. If a subject did not use any chest tube the duration is set to 0. As a sensitivity analysis, subjects with no use of chest tube will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed duration of chest tube drainage will be used.

    Time frame: 28 Days

  10. Length of Time of Intubation

    The length will be derived as the time in hours from separation from CPB until discontinuation of intubation. Any duration of re-use of intubation will continue to accrue. If a subject did not use any intubation the length is set to 0. As a sensitivity analysis, subjects with no use of intubations will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of time on intubation will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of time on intubation of 28 days. For the length of time on intubation the same analyses as described for the primary endpoint will be applied.

    Time frame: 28 Days

  11. Length of Pediatric Intensive Care Unit (PICU) Stay

    The length of PICU stay will be calculated as the total number of days postoperative until discharge from PICU. For subjects who died before discharge from PICU or before Day 28, respectively, the observed length of PICU stay will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of PICU stay of 28 days. For the length of PICU stay the same analyses as described for the primary endpoint will be applied.

    Time frame: 28 Days

  12. Length of Time on Vasodilators

    Length of time on vasodilators will be measured from first use following separation from bypass, until the subject is discharged from the hospital or at Day 28. The length will be derived as the time in hours from separation from CPB until discontinuation of all vasodilators.

    Time frame: 28 Days

  13. Length of Hospitalization

    The length of hospitalization will be calculated as the total number of days postoperative until discharge from the hospital. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of hospitalization will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of hospitalization of 28 days. The same analyses as described for the primary endpoint will be applied.

    Time frame: 28 Days

  14. Patients With Plasma Concentrations of Citrulline

    Plasma citrulline concentrations will be assessed in both treatment groups to determine the number of patients who reach the therapeutic sustained target plasma citrulline level of ≥100 μmol/L. Blood collection for assessment of plasma citrulline concentrations will be taken prior to surgery, during surgery, 30 minutes post-decannulation after CPB (prior to bolus and 5 minutes after bolus), at the specified post-operative time points (6h, 12h, 24h, 48h), and at hospital discharge or Day 28, whichever occurs first.

    Time frame: 28 Days

  15. Occurrence of Adverse and Serious Adverse Events

    Pre-treatment adverse events and treatment adverse events will be analyzed separately. The number of affected subjects will be reported.

    Time frame: 28 Days

  16. Number of Patients With Refractory Hypotension

    Refractory hypotension is defined as a 20% drop of mean arterial pressure (MAP) below specific age-related criteria for more than 30 minutes. The number of subjects with any refractory hypotension from end of surgery until 48 hours will be compared between groups.

    Time frame: 2 Days

07

Results

Posted Feb 23, 2023
Limitations and caveats
Data were significantly skewed due to differences in standard of care between US and non-US. The US dataset met the primary endpoint due to consistent early extubation in the OR. L-Citrulline promoted early extubation, reduced ventilator time \& inotrope use in the US population. Post-hoc analyses gave a significant primary endpoint with an L-Citrulline therapeutic window of 100 µmol ±20% steady state concentration. A second Phase 3 RCT to be conducted in the US alone should confirm this result.

Participant flow

Participant flow — Overall Study
MilestoneL-citrullinePlacebo
Started9990
Completed9690
Not completed30
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryA Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.

Mechanical ventilation (MV) = invasive or noninvasive MV incl. bilevel (biphasic) positive airway pressure or continuous positive airway pressure. Inotrope use = medications considered within the derivation of total inotrope score (dopamine, dobutamine, milrinone, epinephrine, phenylephrine, norepinephrine). Both measures recorded until earliest of subject hospital discharge or Day 28.

Time frame:
28 Days
Reported as:
Mean · Minutes
A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.
MinutesL-citrullinePlacebo
A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.3351.1 ± 5230.83549.6 ± 6069.1
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.4930
SecondaryLength of Time on Mechanical Ventilation

The same definitions and analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time on Mechanical Ventilation
MinutesL-citrullinePlacebo
Length of Time on Mechanical Ventilation2398.4 ± 2031.85236.9 ± 4714.7
SecondaryLength of Time on Positive Pressure Ventilation

The same definitions and analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time on Positive Pressure Ventilation
MinutesL-citrullinePlacebo
Length of Time on Positive Pressure Ventilation2018.7 ± 4918.51285.6 ± 2354.8
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1924
SecondaryLength of Time of Inotrope Use

The same definitions and analyses as described for the primary endpoint will be applied.

Time frame:
28 days
Reported as:
Mean · Minutes
Length of Time of Inotrope Use
MinutesL-citrullinePlacebo
Length of Time of Inotrope Use2726.4 ± 3637.53167.3 ± 6035.2
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.8678
SecondaryInotrope Score

Inotrope score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower inotrope score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower inotrope score in the citrulline group when compared to the placebo group. In this study, the score was calculated each hour post-operatively from the time of separation from bypass until the completion of study drug. Additionally, the total inotrope score over time until Day 28 or hospital discharge was derived. Inotrope score was calculated using the following formula: Total inotrope score = Dopamine dose (µg/kg/min) + Dobutamine dose (µg/kg/min) + 10 \* Milrinone dose (µg/kg/min) + 100 \* Epinephrine dose (µg/kg/min) + 100 \* Phenylephrine dose (µg/kg/min) + 100 \* Norepinephrine dose (µg/kg/min).

Time frame:
Up to 48 hours after separation from CBP
Reported as:
Mean · µg/kg/min
Inotrope Score
µg/kg/minL-citrullinePlacebo
1 hour after separation from CBP1691.6 ± 11420.8583.6 ± 4879.0
2 hours after separation from CBP5076.2 ± 38880.0537.1 ± 4870.3
3 hours after separation from CBP5983.4 ± 39369.21258.2 ± 11744.0
4 hours after separation from CBP6044.1 ± 39566.91257.4 ± 11744.1
5 hours after separation from CBP6044.0 ± 39567.01257.3 ± 11744.1
6 hours after separation from CBP5983.5 ± 39369.21243.4 ± 11677.9
7 hours after separation from CBP5983.3 ± 39369.21243.4 ± 11677.9
8 hours after separation from CBP5983.2 ± 2007.739369.2 ± 13688.2
9 hours after separation from CBP5983.4 ± 39369.22007.1 ± 13688.3
10 hours after separation from CBP5983.0 ± 39369.32007.0 ± 13688.4
11 hours after separation from CBP5983.1 ± 39369.22007.0 ± 13688.4
12 hours after separation from CBP5983.5 ± 39369.22006.8 ± 13688.4
13 hours after separation from CBP5983.1 ± 39369.22006.7 ± 13688.4
14 hours after separation from CBP3255.8 ± 16449.22006.6 ± 13688.4
15 hours after separation from CBP3255.8 ± 16449.22006.5 ± 13688.4
16 hours after separation from CBP3255.4 ± 16449.22006.6 ± 13688.4
17 hours after separation from CBP3255.7 ± 16449.22006.5 ± 13688.4
18 hours after separation from CBP3255.4 ± 16449.22006.2 ± 13688.5
19 hours after separation from CBP3254.9 ± 16449.32006.1 ± 13688.5
20 hours after separation from CBP3254.9 ± 16449.32005.7 ± 13688.5
21 hours after separation from CBP2143.6 ± 12376.32107.8 ± 13707.6
22 hours after separation from CBP2143.2 ± 12376.32005.7 ± 13688.5
23 hours after separation from CBP2143.2 ± 12376.32005.6 ± 13688.6
24 hours after separation from CBP2143.0 ± 12376.42005.3 ± 13688.6
25 hours after separation from CBP2142.8 ± 12376.42005.2 ± 13688.6
26 hours after separation from CBP2142.8 ± 12376.42004.9 ± 13688.7
27 hours after separation from CBP2041.4 ± 2004.912352.5 ± 13688.7
28 hours after separation from CBP2041.1 ± 12352.52005.4 ± 13688.6
29 hours after separation from CBP2041.1 ± 12352.52004.7 ± 13688.7
30 hours after separation from CBP2041.1 ± 12352.52004.7 ± 13688.7
31 hours after separation from CBP2040.9 ± 12352.62004.6 ± 13688.7
32 hours after separation from CBP2041.0 ± 12352.52004.7 ± 13688.7
33 hours after separation from CBP2041.1 ± 12352.52004.6 ± 13688.7
34 hours after separation from CBP2041.0 ± 12352.52004.6 ± 13688.7
35 hours after separation from CBP2040.9 ± 12352.52004.4 ± 13688.7
36 hours after separation from CBP2041.1 ± 12352.52004.5 ± 13688.7
37 hours after separation from CBP2040.9 ± 12352.52004.4 ± 13688.7
38 hours after separation from CBP2040.9 ± 12352.62004.4 ± 13688.7
39 hours after separation from CBP2040.9 ± 12352.62004.3 ± 13688.7
40 hours after separation from CBP1012.5 ± 7071.82004.3 ± 13688.8
41 hours after separation from CBP1012.5 ± 7071.81282.1 ± 8736.4
42 hours after separation from CBP1012.5 ± 7071.8780.0 ± 7378.4
43 hours after separation from CBP1012.4 ± 7071.8779.9 ± 7378.4
44 hours after separation from CBP1012.4 ± 7071.8780.1 ± 7378.4
45 hours after separation from CBP1012.3 ± 7071.8780.0 ± 7378.4
46 hours after separation from CBP1012.1 ± 7071.9780.0 ± 7378.4
47 hours after separation from CBP1012.1 ± 7071.8780.0 ± 7378.4
48 hours after separation from CBP1012.1 ± 7071.9779.8 ± 7378.4
SecondaryHemodynamic Improvement: Heart Rate

Heart rate at hours 1, 2, 4, 12, 24 and 48.

Time frame:
2 Days
Reported as:
Mean · Beats per minute
Hemodynamic Improvement: Heart Rate
Beats per minuteL-citrullinePlacebo
1 hour80.1 ± 67.983.6 ± 60.1
2 hours111.2 ± 45.7116.0 ± 46.7
4 hours130.4 ± 27.7133.5 ± 20.1
12 hours120.9 ± 22.0161.9 ± 17.6
24 hours122.2 ± 22.2118.3 ± 14.9
48 hours125.9 ± 18.7125.4 ± 21.0
SecondaryHemodynamic Improvement: Systemic Arterial Blood Pressure

Systemic arterial blood pressure at hours 1, 2, 4, 12, 24 and 48.

Time frame:
2 Days
Reported as:
Mean · Millimeters of mercury
Hemodynamic Improvement: Systemic Arterial Blood Pressure
Millimeters of mercuryL-citrullinePlacebo
1 hour18.4 ± 16.215.3 ± 14.9
2 hours31.7 ± 17.932.5 ± 18.2
4 hours42.4 ± 12.142.1 ± 12.3
12 hours39.7 ± 12.140.7 ± 10.6
24 hours41.0 ± 12.240.1 ± 10.8
48 hours40.3 ± 15.842.1 ± 11.6
SecondaryHemodynamic Improvement: Oxygen Saturation

Oxygen saturation at hours 1, 2, 4, 12, 24 and 48.

Time frame:
2 Days
Reported as:
Mean · Percentage of hemoglobin bound to oxygen
Hemodynamic Improvement: Oxygen Saturation
Percentage of hemoglobin bound to oxygenL-citrullinePlacebo
1 hour97.2 ± 7.995.7 ± 15.8
2 hours98.6 ± 4.697.6 ± 10.7
4 hours98.5 ± 2.198.1 ± 2.7
12 hours97.9 ± 2.497.6 ± 2.6
24 hours97.1 ± 4.097.6 ± 2.7
48 hours97.6 ± 2.897.8 ± 2.6
SecondaryHemodynamic Improvement: Central Venous Pressure

Central venous pressure at hours 1, 2, 4, 12, 24 and 48.

Time frame:
2 Days
Reported as:
Mean · Millimeters of mercury
Hemodynamic Improvement: Central Venous Pressure
Millimeters of mercuryL-citrullinePlacebo
1 hour10.2 ± 20.112.9 ± 28.0
72 hours10.3 ± 5.613.2 ± 23.9
4 hours13.1 ± 23.713.2 ± 27.4
12 hours9.7 ± 4.19.0 ± 3.6
24 hours10.9 ± 5.49.8 ± 3.6
48 hours11.8 ± 6.29.6 ± 8.3
SecondaryThoracotomy Output

The thoracotomy output is defined as the total volume of chest tube drainage recorded in cc prior to discontinuation of chest intubation. The total postoperative duration (in hours) that the chest tube is used will be calculated as the time from the end of the surgery to the time the chest tube is removed. If an additional chest tube is required or reinserted (until discharge from the hospital or at Day 28) the duration that the additional chest tube was used (from time of insertion to time of removal) will be added to the time the original chest tube was used for the total postoperative duration. If a subject did not use any chest tube the duration is set to 0. As a sensitivity analysis, subjects with no use of chest tube will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed duration of chest tube drainage will be used.

Time frame:
28 Days
Reported as:
Mean · Milliliters
Thoracotomy Output
MillilitersL-citrullinePlacebo
Thoracotomy Output206.41 ± 137.26198.94 ± 143.85
SecondaryLength of Time of Intubation

The length will be derived as the time in hours from separation from CPB until discontinuation of intubation. Any duration of re-use of intubation will continue to accrue. If a subject did not use any intubation the length is set to 0. As a sensitivity analysis, subjects with no use of intubations will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of time on intubation will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of time on intubation of 28 days. For the length of time on intubation the same analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time of Intubation
MinutesL-citrullinePlacebo
Length of Time of Intubation1600.4 ± 4488.91303.9 ± 4408.3
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.6422
SecondaryLength of Pediatric Intensive Care Unit (PICU) Stay

The length of PICU stay will be calculated as the total number of days postoperative until discharge from PICU. For subjects who died before discharge from PICU or before Day 28, respectively, the observed length of PICU stay will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of PICU stay of 28 days. For the length of PICU stay the same analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Days
Length of Pediatric Intensive Care Unit (PICU) Stay
DaysL-citrullinePlacebo
Length of Pediatric Intensive Care Unit (PICU) Stay6.3 ± 8.56.5 ± 9.2
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.7572
SecondaryLength of Time on Vasodilators

Length of time on vasodilators will be measured from first use following separation from bypass, until the subject is discharged from the hospital or at Day 28. The length will be derived as the time in hours from separation from CPB until discontinuation of all vasodilators.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time on Vasodilators
MinutesL-citrullinePlacebo
Length of Time on Vasodilators1668.4 ± 5751.6611.3 ± 1212.5
SecondaryLength of Hospitalization

The length of hospitalization will be calculated as the total number of days postoperative until discharge from the hospital. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of hospitalization will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of hospitalization of 28 days. The same analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Days
Length of Hospitalization
DaysL-citrullinePlacebo
Length of Hospitalization7.1 ± 5.13.9 ± 3.9
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.3681
SecondaryPatients With Plasma Concentrations of Citrulline

Plasma citrulline concentrations will be assessed in both treatment groups to determine the number of patients who reach the therapeutic sustained target plasma citrulline level of ≥100 μmol/L. Blood collection for assessment of plasma citrulline concentrations will be taken prior to surgery, during surgery, 30 minutes post-decannulation after CPB (prior to bolus and 5 minutes after bolus), at the specified post-operative time points (6h, 12h, 24h, 48h), and at hospital discharge or Day 28, whichever occurs first.

Time frame:
28 Days
Reported as:
Mean · umol/L
Patients With Plasma Concentrations of Citrulline
umol/LL-citrullinePlacebo
Day 0 - Intra-Op2179.6 ± 1046.826.4 ± 9.1
Day 0 - 0 hours (prior to bolus)1808.9 ± 12549.427.6 ± 11.3
Day 0 - 0 hours (post bolus)1387.8 ± 4957.527.8 ± 11.6
Day 0 - 6 hours146.6 ± 67.320.3 ± 10.2
Day 0 - 12 hours123.8 ± 41.318.5 ± 8.4
Day 1 - 24 hours102.1 ± 42.614.9 ± 6.8
Day 2 - 48 hours68.2 ± 44.912.1 ± 5.8
Day 28/ Discharge21.9 ± 29.516.9 ± 6.2
SecondaryOccurrence of Adverse and Serious Adverse Events

Pre-treatment adverse events and treatment adverse events will be analyzed separately. The number of affected subjects will be reported.

Time frame:
28 Days
Reported as:
Count of participants · Participants
Occurrence of Adverse and Serious Adverse Events
ParticipantsL-citrullinePlacebo
Any adverse event6862
Pre-treatment adverse events1912
Treatment emergent adverse events6861
Any serious adverse event116
SecondaryNumber of Patients With Refractory Hypotension

Refractory hypotension is defined as a 20% drop of mean arterial pressure (MAP) below specific age-related criteria for more than 30 minutes. The number of subjects with any refractory hypotension from end of surgery until 48 hours will be compared between groups.

Time frame:
2 Days
Reported as:
Count of participants · Participants
Number of Patients With Refractory Hypotension
ParticipantsL-citrullinePlacebo
Number of Patients With Refractory Hypotension00
Post-hocA Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.

Mechanical ventilation (MV) = invasive or noninvasive MV incl. bilevel (biphasic) positive airway pressure or continuous positive airway pressure. Inotrope use = medications considered within the derivation of total inotrope score (dopamine, dobutamine, milrinone, epinephrine, phenylephrine, norepinephrine). Both measures recorded until earliest of subject hospital discharge or Day 28. Note: data are reported for post-hoc analyses based on a modified full analysis set (mFAS) targeting the US population for a 48-hour treatment period. Analysis method used was quartiles based, but followed prescribed statistical analysis plan methods. This is because chosen endpoints did not appear to be valid in the ex-US population due to differences in physician decision making. In the US, extubation occurs as soon as a patient's physical condition permits (only more severely ill children remain on mechanical ventilation); conversely, in ex-US sites, children remain on mechanical ventilation.

Time frame:
28 Days
Reported as:
Mean · Minutes
A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.
MinutesL-citrullinePlacebo
A Composite Variable Consisting of the Longer of Either (1) Length of Time on Mechanical Ventilation or (2) Length of Inotrope Use.1484.9 ± 1317.11730.7 ± 1435.5
Statistical analysis
  • L-citrulline vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1560 (The threshold for statistical significance was p = 0.05) · Location shift: 219.0 · 95% CI -88.0 to 626.0Treatment difference = L-citrulline - placebo For the mean and median values, that the estimated values are given in minutes \[min\]
  • L-citrulline vs Placebo · t-test, 2 sided · p = 0.1627 (The threshold for statistical significance was 0.05.) · Location shift: 813.1 · 95% CI -335.5 to 1961.6Treatment difference = L-citrulline - placebo. For the mean and median values, the estimated values are given in minutes
Post-hocLength of Time on Mechanical Ventilation

The same definitions and analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time on Mechanical Ventilation
MinutesL-citrullinePlacebo
Length of Time on Mechanical Ventilation420.2 ± 585.1649.7 ± 786.4
Post-hocLength of Time on Positive Pressure Ventilation

The same definitions and analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time on Positive Pressure Ventilation
MinutesL-citrullinePlacebo
Length of Time on Positive Pressure Ventilation200.9 ± 560.5358.0 ± 758.5
Post-hocLength of Time of Inotrope Use

The same definitions and analyses as described for the primary endpoint will be applied.

Time frame:
28 days
Reported as:
Mean · Minutes
Length of Time of Inotrope Use
MinutesL-citrullinePlacebo
Length of Time of Inotrope Use1428.6 ± 1344.61653.1 ± 1485.7
Post-hocInotrope Score

Inotrope score is reflective of the pharmacological support required by the cardiovascular system and is a good predictor of mortality and morbidity in patients undergoing bypass surgery. A lower inotrope score represents less pharmacological support and would indicate a lower risk for a poor clinical outcome. Therefore, any treatment effect would be indicated by a lower inotrope score in the citrulline group when compared to the placebo group. In this study, the score was calculated each hour post-operatively from the time of separation from bypass until the completion of study drug. Additionally, the total inotrope score over time until Day 28 or hospital discharge was derived. Inotrope score was calculated using the following formula: Total inotrope score = Dopamine dose (µg/kg/min) + Dobutamine dose (µg/kg/min) + 10 \* Milrinone dose (µg/kg/min) + 100 \* Epinephrine dose (µg/kg/min) + 100 \* Phenylephrine dose (µg/kg/min) + 100 \* Norepinephrine dose (µg/kg/min).

Time frame:
28 Days
Reported as:
Mean · µg/kg/min
Inotrope Score
µg/kg/minL-citrullinePlacebo
Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after separation from CBP14.7 ± 43.017.4 ± 44.8
Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after separation from CBP17.2 ± 98.013.5 ± 58.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 3 hours after separation from CBP4.5 ± 4.24.5 ± 3.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after separation from CBP3.6 ± 2.64.4 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 5 hours after separation from CBP3.7 ± 2.84.4 ± 2.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 6 hours after separation from CBP3.7 ± 2.84.4 ± 2.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 7 hours after separation from CBP3.6 ± 2.74.5 ± 3.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 8 hours after separation from CBP3.4 ± 2.44.5 ± 3.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 9 hours after separation from CBP3.4 ± 2.44.4 ± 3.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 10 hours after separation from CBP3.4 ± 2.44.3 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 11 hours after separation from CBP3.3 ± 2.54.1 ± 2.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after separation from CBP3.4 ± 3.54.0 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 13 hours after separation from CBP3.3 ± 2.83.8 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 14 hours after separation from CBP3.1 ± 2.53.7 ± 3.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 15 hours after separation from CBP3.1 ± 2.63.7 ± 3.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 16 hours after separation from CBP3.0 ± 2.63.5 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 17 hours after separation from CBP3.1 ± 2.83.8 ± 4.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 18 hours after separation from CBP3.0 ± 2.73.4 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 19 hours after separation from CBP2.8 ± 2.73.4 ± 3.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 20 hours after separation from CBP2.9 ± 3.23.1 ± 3.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 21 hours after separation from CBP2.6 ± 2.83.1 ± 3.8
Patients on mechanical ventilation for ≤48 hours (US patients) - 22 hours after separation from CBP2.3 ± 2.72.7 ± 3.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 23 hours after separation from CBP2.2 ± 3.22.9 ± 4.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after separation from CBP2.1 ± 3.12.3 ± 3.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 25 hours after separation from CBP1.8 ± 2.62.4 ± 4.0
Patients on mechanical ventilation for ≤48 hours (US patients) - 26 hours after separation from CBP1.7 ± 2.81.9 ± 3.0
Patients on mechanical ventilation for ≤48 hours (US patients) - 27 hours after separation from CBP1.5 ± 2.71.8 ± 2.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 28 hours after separation from CBP1.4 ± 2.32.0 ± 3.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 29 hours after separation from CBP1.3 ± 2.31.5 ± 2.8
Patients on mechanical ventilation for ≤48 hours (US patients) - 30 hours after separation from CBP1.4 ± 2.51.4 ± 2.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 31 hours after separation from CBP1.2 ± 2.31.4 ± 2.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 32 hours after separation from CBP1.2 ± 2.31.5 ± 3.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 33 hours after separation from CBP1.2 ± 2.41.4 ± 2.7
Patients on mechanical ventilation for ≤48 hours (US patients) - 34 hours after separation from CBP1.1 ± 2.21.3 ± 2.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 35 hours after separation from CBP1.2 ± 2.31.2 ± 2.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 36 hours after separation from CBP1.1 ± 2.21.3 ± 2.7
Patients on mechanical ventilation for ≤48 hours (US patients) - 37 hours after separation from CBP1.1 ± 2.31.2 ± 2.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 38 hours after separation from CBP1.0 ± 2.11.2 ± 2.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 39 hours after separation from CBP1.0 ± 2.11.1 ± 2.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 40 hours after separation from CBP1.0 ± 2.11.1 ± 2.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 41 hours after separation from CBP0.9 ± 2.11.1 ± 2.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 42 hours after separation from CBP1.0 ± 2.31.1 ± 2.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 43 hours after separation from CBP0.8 ± 1.91.0 ± 2.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 44 hours after separation from CBP0.9 ± 2.21.2 ± 2.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 45 hours after separation from CBP0.7 ± 2.01.0 ± 2.0
Patients on mechanical ventilation for ≤48 hours (US patients) - 46 hours after separation from CBP0.6 ± 1.41.1 ± 2.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 47 hours after separation from CBP0.6 ± 1.41.0 ± 2.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after separation from CBP0.4 ± 1.20.7 ± 1.5
Post-hocHemodynamic Improvement: Heart Rate

Heart rate will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.

Time frame:
2 Days
Reported as:
Mean · Beats per minute
Hemodynamic Improvement: Heart Rate
Beats per minuteL-citrullinePlacebo
Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after surgery start-43.9 ± 78.6-40.6 ± 66.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after surgery start-14.1 ± 50.01.1 ± 43.0
Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after surgery start10.0 ± 27.318.5 ± 24.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after surgery start1.8 ± 19.65.4 ± 16.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after surgery start3.1 ± 21.33.3 ± 20.3
Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after surgery start5.8 ± 21.27.1 ± 26.6
Post-hocHemodynamic Improvement: Systemic Arterial Blood Pressure

Systemic arterial blood pressure will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.

Time frame:
2 Days
Reported as:
Mean · Millimeters of mercury
Hemodynamic Improvement: Systemic Arterial Blood Pressure
Millimeters of mercuryL-citrullinePlacebo
Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after surgery start-17.9 ± 13.2-22.3 ± 17.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after surgery start-3.8 ± 19.1-4.0 ± 17.8
Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after surgery start7.3 ± 12.58.9 ± 13.5
Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after surgery start6.6 ± 11.77.2 ± 13.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after surgery start8.8 ± 12.98.4 ± 11.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after surgery start6.5 ± 17.97.6 ± 14.5
Post-hocHemodynamic Improvement: Oxygen Saturation

Oxygen saturation will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.

Time frame:
2 Days
Reported as:
Mean · Percentage of hemoglobin bound to oxygen
Hemodynamic Improvement: Oxygen Saturation
Percentage of hemoglobin bound to oxygenL-citrullinePlacebo
Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after surgery start1.3 ± 6.2-1.8 ± 18.2
Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after surgery start2.3 ± 9.41.5 ± 9.0
Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after surgery start1.4 ± 8.80.7 ± 9.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after surgery start0.8 ± 8.40.7 ± 8.7
Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after surgery start-0.2 ± 9.90.2 ± 8.4
Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after surgery start0.4 ± 9.61.1 ± 10.3
Post-hocHemodynamic Improvement: Central Venous Pressure

Central venous pressure will be calculated using the absolute changes from baseline at hours 1, 2, 4, 12, 24 and 48 and will be compared between groups using an ANOVA with a fixed effect for treatment group and baseline level. Summary tables describing descriptive measurements will be generated for absolute values and absolute change from baseline values for all observed time points.

Time frame:
2 Days
Reported as:
Mean · Millimeters of mercury
Hemodynamic Improvement: Central Venous Pressure
Millimeters of mercuryL-citrullinePlacebo
Patients on mechanical ventilation for ≤48 hours (US patients) - 1 hour after treatment-10.0 ± 48.8-6.8 ± 45.0
Patients on mechanical ventilation for ≤48 hours (US patients) - 2 hours after treatment-6.5 ± 47.4-5.2 ± 43.8
Patients on mechanical ventilation for ≤48 hours (US patients) - 4 hours after treatment6.7 ± 36.5-5.2 ± 41.7
Patients on mechanical ventilation for ≤48 hours (US patients) - 12 hours after treatment-10.4 ± 58.6-7.7 ± 41.1
Patients on mechanical ventilation for ≤48 hours (US patients) - 24 hours after treatment-0.1 ± 11.2-8.3 ± 43.9
Patients on mechanical ventilation for ≤48 hours (US patients) - 48 hours after treatment-5.3 ± 17.36.2 ± 20.8
Statistical analysis
  • L-citrulline vs Placebo · ANOVA · p = 0.0326 (The threshold for statistical significance was 0.05.)
  • L-citrulline vs Placebo · ANOVA · p = 0.0026 (The threshold for statistical significance was 0.05.)
Post-hocThoracotomy Output

The thoracotomy output is defined as the total volume of chest tube drainage recorded in cc prior to discontinuation of chest intubation. The total postoperative duration (in hours) that the chest tube is used will be calculated as the time from the end of the surgery to the time the chest tube is removed. If an additional chest tube is required or reinserted (until discharge from the hospital or at Day 28) the duration that the additional chest tube was used (from time of insertion to time of removal) will be added to the time the original chest tube was used for the total postoperative duration. If a subject did not use any chest tube the duration is set to 0. As a sensitivity analysis, subjects with no use of chest tube will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed duration of chest tube drainage will be used.

Time frame:
28 Days
Reported as:
Mean · Milliliters
Thoracotomy Output
MillilitersL-citrullinePlacebo
Thoracotomy Output209.42 ± 141.35194.35 ± 124.41
Post-hocLength of Time of Intubation

The length will be derived as the time in hours from separation from CPB until discontinuation of intubation. Any duration of re-use of intubation will continue to accrue. If a subject did not use any intubation the length is set to 0. As a sensitivity analysis, subjects with no use of intubations will be excluded. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of time on intubation will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of time on intubation of 28 days. For the length of time on intubation the same analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time of Intubation
MinutesL-citrullinePlacebo
Length of Time of Intubation329.9 ± 432.6386.5 ± 556.6
Post-hocLength of Pediatric Intensive Care Unit (PICU) Stay

The length of PICU stay will be calculated as the total number of days postoperative until discharge from PICU. For subjects who died before discharge from PICU or before Day 28, respectively, the observed length of PICU stay will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of PICU stay of 28 days. For the length of PICU stay the same analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Days
Length of Pediatric Intensive Care Unit (PICU) Stay
DaysL-citrullinePlacebo
Length of Pediatric Intensive Care Unit (PICU) Stay5.6 ± 9.27.1 ± 10.7
Post-hocLength of Time on Vasodilators

Length of time on vasodilators will be measured from first use following separation from bypass, until the subject is discharged from the hospital or at Day 28. The length will be derived as the time in hours from separation from CPB until discontinuation of all vasodilators.

Time frame:
28 Days
Reported as:
Mean · Minutes
Length of Time on Vasodilators
MinutesL-citrullinePlacebo
Length of Time on Vasodilators617.9 ± 910.0624.8 ± 1077.1
Post-hocLength of Hospitalization

The length of hospitalization will be calculated as the total number of days postoperative until discharge from the hospital. For subjects who died before discharge from the hospital or before Day 28, respectively, the observed length of hospitalization will be used. As sensitivity analyses subjects who died will (1) be excluded from analysis and (2) be assigned a length of hospitalization of 28 days. The same analyses as described for the primary endpoint will be applied.

Time frame:
28 Days
Reported as:
Mean · Days
Length of Hospitalization
DaysL-citrullinePlacebo
Length of Hospitalization4.9 ± 2.64.8 ± 2.5
Post-hocPatients With Plasma Concentrations of Citrulline

Plasma citrulline concentrations will be assessed in both treatment groups to determine the number of patients who reach the therapeutic sustained target plasma citrulline level of ≥100 μmol/L. Blood collection for assessment of plasma citrulline concentrations will be taken prior to surgery, during surgery, 30 minutes post-decannulation after CPB (prior to bolus and 5 minutes after bolus), at the specified post-operative time points (6h, 12h, 24h, 48h), and at hospital discharge or Day 28, whichever occurs first.

Time frame:
28 Days
Reported as:
Mean · umol/L
Patients With Plasma Concentrations of Citrulline
umol/LL-citrullinePlacebo
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - Intra-Op2264.6 ± 890.126.7 ± 9.5
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 0 hours (prior to bolus)2625.4 ± 16391.925.4 ± 8.8
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 0 hours (post bolus)760.1 ± 369.525.7 ± 9.0
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 6 hours133.7 ± 39.218.8 ± 8.6
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 0 - 12 hours125.6 ± 32.917.6 ± 7.4
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 1 - 24 hours108.4 ± 43.014.6 ± 6.6
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 2 - 48 hours73.3 ± 49.612.4 ± 6.8
Patients on mechanical ventilation for ≤48 hours (US patients) - Day 28/ Discharge28.5 ± 44.316.2 ± 6.4
Post-hocOccurrence of Adverse and Serious Adverse Events

Pre-treatment adverse events and treatment adverse events will be analyzed separately. The number affected subjects will be reported.

Time frame:
28 Days
Reported as:
Count of participants · Participants
Occurrence of Adverse and Serious Adverse Events
ParticipantsL-citrulline - All Patients Off Mechanical Ventilation in ≤48 HoursL-citrulline - US Patients Off Mechanical Ventilation in ≤48 HoursL-citrulline - All Patients Off Mechanical Ventilation in >48 HoursL-citrulline - US Patients Off Mechanical Ventilation in >48 HoursPlacebo - All Patients Off Mechanical Ventilation in ≤48 HoursPlacebo - US Patients Off Mechanical Ventilation in ≤48 HoursPlacebo - All Patients Off Mechanical Ventilation in >48 HoursPlacebo - US Patients Off Mechanical Ventilation in >48 Hours
Any adverse event483020104730158
Pre-treatment adverse events126739631
Treatment emergent adverse events483020104629158
Any serious adverse event42742243
Pre-treatment serious adverse events11110100
Treatment-emergent serious adverse events42742243
Post-hocNumber of Patients With Refractory Hypotension

Refractory hypotension is defined as a 20% drop of mean arterial pressure (MAP) below specific age-related criteria for more than 30 minutes. The number of subjects with any refractory hypotension from end of surgery until 48 hours will be compared between groups.

Time frame:
2 Days

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were recorded from the time of giving informed consent until the Day 28 telephone follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L-citrulline - All Patients0/99 (0%)11/99 (11.1%)68/99 (68.7%)
Placebo - All Patients0/90 (0%)6/90 (6.7%)61/90 (67.8%)
L-citrulline - All Patients on Mechanical Ventilation for ≤48 Hours0/76 (0%)5/76 (6.6%)48/76 (63.2%)
L-citrulline - US Patients on Mechanical Ventilation for ≤48 Hours0/58 (0%)2/58 (3.4%)30/58 (51.7%)
L-citrulline - All Patients on Mechanical Ventilation for >48 Hours0/23 (0%)7/23 (30.4%)20/23 (87%)
L-citrulline - US Patients on Mechanical Ventilation for >48 Hours0/13 (0%)4/13 (30.8%)10/13 (76.9%)
Placebo - All Patients on Mechanical Ventilation for ≤48 Hours0/71 (0%)2/71 (2.8%)46/71 (64.8%)
Placebo - US Patients on Mechanical Ventilation for ≤48 Hours0/54 (0%)2/54 (3.7%)29/54 (53.7%)
Placebo - All Patients on Mechanical Ventilation for >48 Hours1/19 (5.3%)4/19 (21.1%)15/19 (78.9%)
Placebo - US Patients on Mechanical Ventilation for >48 Hours0/12 (0%)3/12 (25%)8/12 (66.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventL-citrulline - All PatientsPlacebo - All PatientsL-citrulline - All Patients on Mechanical Ventilation for ≤48 HoursL-citrulline - US Patients on Mechanical Ventilation for ≤48 HoursL-citrulline - All Patients on Mechanical Ventilation for >48 HoursL-citrulline - US Patients on Mechanical Ventilation for >48 HoursPlacebo - All Patients on Mechanical Ventilation for ≤48 HoursPlacebo - US Patients on Mechanical Ventilation for ≤48 HoursPlacebo - All Patients on Mechanical Ventilation for >48 HoursPlacebo - US Patients on Mechanical Ventilation for >48 Hours
Atrioventricular blockCardiac disorders0/991/900/760/580/230/130/710/541/191/12
Failure to thriveMetabolism and nutrition disorders0/991/900/760/580/230/130/711/541/191/12
Respiratory acidosisRespiratory, thoracic and mediastinal disorders0/991/900/760/580/230/130/710/541/191/12
Swallow study abnormalInvestigations1/990/900/760/581/231/130/710/540/190/12
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/990/900/760/581/231/130/710/540/190/12
Respiratory arrestRespiratory, thoracic and mediastinal disorders1/990/900/760/581/231/130/710/540/190/12
HypotensionVascular disorders1/990/900/760/581/231/130/710/540/190/12
Aortic valve incompetenceCardiac disorders0/991/900/760/580/230/130/710/541/190/12
Atrioventricular block completeCardiac disorders0/991/900/760/580/230/130/711/541/190/12
Cardiac arrestCardiac disorders0/991/900/760/580/230/130/711/541/190/12
Most frequent other events
Showing 10 of 81
Most frequent other events
EventL-citrulline - All PatientsPlacebo - All PatientsL-citrulline - All Patients on Mechanical Ventilation for ≤48 HoursL-citrulline - US Patients on Mechanical Ventilation for ≤48 HoursL-citrulline - All Patients on Mechanical Ventilation for >48 HoursL-citrulline - US Patients on Mechanical Ventilation for >48 HoursPlacebo - All Patients on Mechanical Ventilation for ≤48 HoursPlacebo - US Patients on Mechanical Ventilation for ≤48 HoursPlacebo - All Patients on Mechanical Ventilation for >48 HoursPlacebo - US Patients on Mechanical Ventilation for >48 Hours
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders6/992/902/761/584/234/132/712/540/190/12
RestlessnessPsychiatric disorders14/9914/908/760/586/230/1310/710/544/190/12
Pleural effusionRespiratory, thoracic and mediastinal disorders12/9911/906/761/586/232/137/712/544/190/12
PainGeneral disorders16/9919/9011/761/585/231/1316/712/543/190/12
PyrexiaGeneral disorders19/9913/9014/762/585/232/1311/713/542/191/12
ConstipationGastrointestinal disorders11/9916/908/764/583/230/1312/717/544/192/12
HypertensionVascular disorders12/9912/9010/769/582/232/1312/7110/540/190/12
AtelectasisRespiratory, thoracic and mediastinal disorders7/996/903/760/584/232/134/712/542/191/12
ChylothoraxRespiratory, thoracic and mediastinal disorders5/991/901/761/584/231/131/711/540/191/12
VomitingGastrointestinal disorders6/9912/904/760/582/231/1310/714/542/192/12

Baseline characteristics

Data shown for all patients (N=189). Additionally data are shown for patients within the USA only (N=137), a subset of all patients (N=189), because endpoints did not appear valid ex-US due to differences in standard of care. The estimated enrollment period was 11 months. The total trial period for a patient was up to 42 days (up to 2 weeks screening, 2 days treatment, up to 28 days follow-up). The trial end was defined as "last patient out" (LPO).

Age, Customized
Age, Customized(Months)L-citrullinePlaceboTotal
US Patients off mechanical ventilation in ≤48 hours16.6 ± 28.417.3 ± 29.116.9 ± 28.6
US Patients off mechanical ventilation in >48 hours6.6 ± 6.79.0 ± 11.97.8 ± 9.4
All patients17.4 ± 26.919.5 ± 31.618.4 ± 29.2
Sex: Female, Male
Sex: Female, Male(Participants)L-citrullinePlaceboTotal
USA patients — Female243256
USA patients — Male342256
All patients — Female455398
All patients — Male543791
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)L-citrullinePlaceboTotal
USA patients — Hispanic or Latino5813
USA patients — Not Hispanic or Latino534598
USA patients — Unknown or Not Reported011
All patients — Hispanic or Latino81220
All patients — Not Hispanic or Latino9177168
All patients — Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)L-citrullinePlaceboTotal
United States6671137
Israel192241
Europe5611
08

Study locations

29 sites
  • University of Alabama
    Birmingham, Alabama 35233, United States
  • Loma Linda University Children's Hospital
    Loma Linda, California 92354, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Arnold Palmer Hospital for Children
    Orlando, Florida 32806, United States
  • Advocate Children's Hospital
    Oak Lawn, Illinois 60453, United States
  • Riley Hospital for Children at Indiana University
    Indianapolis, Indiana 46202, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216-4505, United States
  • St Louis University, SSM Health Cardinal Glennon Children's Hospital
    Saint Louis, Missouri 63104, United States
  • Washington University School of Medicine/ St Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • The Children's Hospital at Montefiore
    Bronx, New York 10467, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43215, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin
    Madison, Wisconsin 53792-1690, United States
  • LKH-Universitätsklinikum Graz Universitätsklinik für Kinder- und Jugendheilkunde
    Graz, 8036, Austria
  • Medizinische Universität Wien, Klinik für Kinder- und Jugendheilkunde, Abteilung für Pädiatrische Kardiologie Kinderherzzentrum
    Wien, 1050, Austria
  • Universitätsmedizin Göttingen
    Göttingen, 37075, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Klinik für Kinderkardiologie und angeborene Herzfehler. Deutsches Herzzentrum München - Klinik an der TU München
    München, 80636, Germany
  • Universitätsklinik Tübingen, Kinderkardiologie Pulmonologie, Intensivmedizin
    Tübingen, Tübingen, Germany
  • Rambam Health Care Center
    Haifa, 3109601, Israel
  • Wolfson Medical Center
    H̱olon, 5822012, Israel
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jun 2019, 34 months.

Results were first posted in Feb 2023, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2016
First posted
Sep 8, 2016
StartActual
Aug 2016
Primary completionActual
Jun 2019
CompletionActual
Jul 2019
Results first posted
Feb 23, 2023
Last update
Feb 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02891837
Lead sponsor
Asklepion Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Sep 8, 2016
Start date
Aug 2016
Primary completion
Jun 2019
Completion
Jul 2019
Results posted
Feb 23, 2023
Last update
Feb 23, 2023

Study contacts

Gurdyal Kalsi, MD
study director · Asklepion Pharmaceuticals, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Citrulline

Start the discussion